Drug Target Review

FEBRUARY 14, 2024

Researchers from the Michigan State University have created an advanced human heart organoid system that models the characteristics of pregestational diabetes-induced congenital heart disease found in mice and humans. The most common type of congenital defect in humans is congenital heart disease.

Disease 59

Disease Research Drugs 59

The Pharma Data

NOVEMBER 24, 2020

Contraceptive Use Low Among Women With Kidney Disease. 24, 2020 — Contraceptive use is low among women of reproductive age undergoing dialysis for end-stage kidney disease, according to a study published online Oct. TUESDAY, Nov. 26 in Kidney Medicine. Silvi Shah, M.D.,

Disease 52

Disease Research 52

Chemical Biology and Drug Design

NOVEMBER 13, 2023

SARS-CoV-2 is responsible for the coronavirus disease of 2019 (COVID-19) which is one of the most widespread and powerful infections affecting human lungs. WHO proclaimed the outbreak of the Ebola virus disease (EVD), in 2014 that killed hundreds of people in West Africa.

Vaccine 100

Vaccine Laboratories RNA Clinical Development 100

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease 52

Disease Science Therapies Production 52

Broad Institute

SEPTEMBER 15, 2023

We apply STACI to analyze the spatio-temporal progression of Alzheimer’s disease and identify the associated nuclear morphometric and coupled gene expression features.

Disease 40

Disease 40

The Pharma Data

DECEMBER 18, 2020

18 December 2020 — The US Food and Drug Administration (FDA) has requested further clarifying analyses of clinical data, to complete its review of the New Drug Application (NDA) for roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for patients with anemia of chronic kidney disease (CKD). Bikbov B et al.

Disease 52

Disease FDA FDA Approval Treatment 52

Broad Institute

NOVEMBER 7, 2023

While RA therapies targeted to specific inflammatory pathways have emerged, only some patients’ symptoms improve with treatment, emphasizing the need for multiple treatment approaches tailored to different disease subtypes. They also found that patients’ CTAPs were dynamic and could change over time in response to treatment.

Treatment 96

Treatment RNA Hospitals Disease 96

Drug Target Review

OCTOBER 17, 2023

Metabolic changes and tumourigenicity Cancer is a multi-faceted disease which has previously been seen as a disorder in cell proliferation, the increase in cell numbers resulting from cell division. Waltham, MA: Academic Press, Imprint of Elsevier; 2014 [cited 2023 October 11] p.761-5. References 1 Krafts K, Ray SD, Yang N.

Regulations 98

Regulations Therapies Treatment Disease 98

Drug Target Review

SEPTEMBER 4, 2023

There have been several studies that have reported the ability of infectious disease agents to be drug resistant. Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. They could be spread by physical contact, airborne, waterborne, foodborne, or vector-borne.

Drugs 111

Drugs RNA DNA Disease 111

PLOS: DNA Science

MARCH 21, 2024

Lenmeldy adds functional genes that encode the enzyme arylsulfatase A (ARSA) to bone marrow stem cells taken from children who have inherited the disease, but haven’t yet developed symptoms, which typically begin around age 2 or 3. Each of their children would face a 1 in 4 chance of inheriting the disease.

Therapies 98

Therapies Clinical Trials DNA Trials 98

Drug Target Review

JUNE 9, 2023

C ould you explain the specific mechanisms or techniques used in the pre-clinical research to translate the genetics of the adaptive immune system into clinical products for disease detection and treatment? What types of diseases or conditions were targeted in the pre-clinical research phase? a healthcare informatics company.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. This led to the eradication of smallpox and polio – two debilitating diseases that historically caused global epidemics. Let’s take a deeper dive into these challenges.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Science 98

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Dr Huimin Cao Senior Research Fellow, Cartherics Dr Madeline Cao received her MD in 2010 and practiced at Institute of Hematology & Blood Diseases Hospital in Tianjin, China.

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. It is designed for use in a broad infant population, including all infants experiencing their first RSV season and infants with congenital heart disease or chronic lung disease entering their first and second RSV season.

Virus 40

Virus Trials Disease Hospitals 40

The Pharma Data

JANUARY 20, 2021

Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet ® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). About Unclassifiable Interstitial Lung Disease. Since its U.S. About the Pivotal Study. Esbriet U.S.

FDA 40

FDA Disease Doctors Treatment 40

Drug Target Review

FEBRUARY 28, 2024

Prior to the founding of IN8bio, from 2014 to 2017, Mr Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Human γδ TCR repertoires in health and disease. Mr Ho has worked in the biotechnology industry for almost 20 years. References Fichtner A, Ravens S, Prinz I. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

NIH Director's Blog: Drug Development

APRIL 18, 2017

Some of those variations can knock out the function of a gene in ways that lead to disease or other serious health problems, particularly in people unlucky enough to have two malfunctioning copies of the same gene. The PROMIS study serves as resource for researchers to study various aspects of heart disease, including its genetics.

Drugs 52

Drugs DNA Disease Drug Development 52

The Pharma Data

MARCH 11, 2021

Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs. Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient ma. Without accurate diagnosis, appropriate disease management may be delayed.

Disease 52

Disease Treatment Laboratories Virus 52

The Pharma Data

JULY 22, 2021

Researchers in the field of parasitology celebrated for contributions early in their scientific careers Together with scientific publisher Parasites & Vector, Boehringer Ingelheim has sponsored the award since its founding in 2014 Award serves to foster career growth in parasitology as well as keep memory of parasitologist Odile Bain alive.

Research 52

Research Disease Science Treatment 52

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Disease 98

Disease Bioinformatics Medical Schools Research 98

Drug Target Review

AUGUST 24, 2023

These findings were mirrored in the clinical results from an analysis of two metastatic melanoma patient cohorts who received anti-PD-1 treatment: patients with responses and disease control had significantly lower GDF-15 serum levels (measured before treatment start), while none of the patients with elevated GDF-15 levels showed a lasting response.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

The Pharma Data

MAY 5, 2021

Farxiga use expanded for reducing risks in patients with chronic kidney disease. The SGLT2 inhibitor was originally approved in 2014 to improve glycemic control in adults with type 2 diabetes in addition to diet and exercise. . controlled trial had not received previous systemic therapy for metastatic disease. blind, placebo?controlled

FDA Approval 52

FDA Approval FDA Therapies Pharmacokinetics 52

The Pharma Data

SEPTEMBER 22, 2020

MSD’s therapy also cut the risk of disease progression or death in half compared to chemotherapy, and 81.4% Before 2014, the five-year survival rate for patients in the U.S. MSD’s therapy also cut the risk of disease progression or death in half compared to chemotherapy, and 81.4% Objective response rate was measured at 46.1%

Therapies 52

Therapies Treatment Disease Research 52

Drug Target Review

JANUARY 5, 2024

Dr Ben Lehner, Senior Group Leader at the Wellcome Sanger Institute and senior author of the study concluded: “The big challenge in medicine isn’t knowing which proteins are causing diseases but not knowing how to control them. 2014 January 3 [2023 December 19]; 39(2):91-100. This study was published in Nature. Available from: [link]

Regulations 98

Regulations Pharmaceutical Companies DNA Drug Development 98

NIH Director's Blog: Drug Discovery

DECEMBER 9, 2014

Tanzi, Massachusetts General Hospital/ Harvard Medical School Researchers want desperately to develop treatments to help the more than 5 million Americans with Alzheimer’s disease and the millions more at risk. The answer appears to lie in their decision to add a third dimension to their disease model.

Drugs 52

Drugs Disease Hospitals Medical Schools 52

The Pharma Data

AUGUST 12, 2020

The trial also met it primary endpoints of disease-free survival. Opdivo was first approved for use in July 2014, and is now approved in more than 65 countries. The overall survival benefit was seen in the randomised population and the study met its two primary endpoints of overall survival and progression-free survival.

Clinical Trials 52

Clinical Trials Trials Therapies Treatment 52

The Pharma Data

SEPTEMBER 30, 2020

The suit was originally brought by Tom Jefferson, an epidemiologist and Cochrane Collaboration researcher, in 2014. A Maryland federal judge denied Roche’s motion to throw out a lawsuit that alleges the company defrauded the US and state governments through misrepresenting Tamiflu’s benefit in combating the flu. .

Government 52

Government Trials Disease Production 52

DrugBank

JUNE 27, 2023

Out of the millions of genetic variants present in human populations, GWAS are designed to uncover those associated with specific traits or diseases. 9 Polygenic diseases are much more common, and thousands of genetic variants with very small effects could impact their phenotype.

Disease 98

Disease Treatment Drugs Clinical Trials 98

The Pharma Data

NOVEMBER 10, 2020

P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Oral and nasal administration routes are both physiologic approaches to stimulate the mucosal immune system to induce disease modifying benefits.”.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

OCTOBER 23, 2020

Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Coverage with at least two doses of influenza vaccine was higher for children born during 2016 to 2017 versus 2014 to 2015 (58.1 FRIDAY, Oct. 23 issue of the U.S. 90 percent, although in 14 states MMR coverage was <90 percent. percent, respectively.

Vaccine 52

Vaccine Disease Research 52

Eye on FDA

JUNE 14, 2023

The numbers plummet in 2014 until the record low last year of only 4 letters. The latest letter was issued for a website that promoted a treatment for hypercortisolemia in patients with Cushings Disease. That is the record high for a single year since that time and means that they were coming out a rate of over 12 a month on average.

FDA 82

FDA Production Doctors Treatment 82

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). in individuals newly treated with lecanemab and was presented at the 2021 Alzheimer’s Disease and Parkinson’s Disease Conference. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease.

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

OCTOBER 15, 2020

“Despite the 2014 approval of two oral antifibrotic therapies, IPF and other fibrotic lung diseases remain fatal diseases with substantial unmet need. IPF and other fibrotic lung diseases are characterized by progressive scarring, reduced exercise capacity and ultimate death from respiratory failure and/or co-morbidities.

Trials 40

Trials Therapies Disease Licensing 40

The Premier Consulting Blog

JUNE 26, 2023

In this blog post, we review the regulatory programs available to expedite treatments for rare disorders and serious diseases. 2 The regulations also reflect the agency’s recognition that patients and physicians might be willing to accept greater treatment-related risks for life-threatening or severely debilitating diseases.

FDA 52

FDA Clinical Trials Therapies Trials 52

The Pharma Data

AUGUST 19, 2020

New York State also says Teva made 20% of all opioids distributed from 2006 to 2014 in the region and marketed its products for off-label uses. The Centers for Disease Control and Prevention has estimated that opioids have contributed to more than 400,000 deaths since 1997. . Both companies deny the charges. . Conor Kavanagh.

Pharmaceuticals 52

Pharmaceuticals Doctors International FDA 52

NIH Director's Blog: Drug Development

JUNE 14, 2016

People with type 2 diabetes are at increased risk for heart attacks, stroke, and other forms of cardiovascular disease, and at an earlier age than other people. In fact, the evidence suggests that such drugs might even offer some protection against heart disease. 2014 Jan;32(1):40-51. Food and Drug Administration. Novo Nordisk.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52